

Prostate Cancer Quarterly Benchmarks Report
Fiscal Year 2012 4th Quarter Report

Maryland Department of Health and Mental Hygiene
 Center for Cancer Surveillance and Control
 Cancer Prevention, Education, Screening, and Treatment Program

Jurisdiction/Program: ALL

Sponsor: CRF

			Period:	7/1-9/30	10/1-12/31	1/1-3/31	4/1-6/30	7/1-6/30
			Run Date:	01/13/2012	04/06/2012	07/19/2012	10/10/2012	10/10/2012
Category	No.	Indicator	Standard	FY12 1Q	FY12 2Q	FY12 3Q	FY12 4Q	FY12 Total
Screening Priority Population	1	Percent of prostate cancer screenngs with both PSA and DRE	≥80%	96.9	100.0	97.1	100.0	98.2
Case Management Among Program-eligible Clients	2	Percent of prostate cancer screenings* with abnormal findings/needs further evaluation to rule out cancer with a diagnosis status of 'Complete'	≥80%	100.0	No Data	100.0	100.0	100.0
	3	Percent of prostate cancer screenings* with abnormal findings/needs further evaluation to rule out cancer with date of diagnosis within 90 days of screening among those with diagnosis status of 'Complete'	≥80%	100.0	No Data	100.0	100.0	76.9
	4	Percent of prostate cancers diagnosed with treatment started	≥80%	No Data	50.0	No Data	100.0	66.7
	5	Percent of prostate cancers with treatment started within 60 days of diagnosis among those who started treatment	≥80%	No Data	100.0	No Data	0.0	50.0
	6	Percent of prostate cancers with stage information among clients diagnosed with cancer who had surgery	≥80%	80.0	100.0	0.0	0.0	57.1
Notification	7	Percent of PSA results received by the program within 28 days of test	≥80%	100.0	100.0	100.0	100.0	100.0
	8	Percent of men ever notified of screening* results by program	≥95%	100.0	100.0	100.0	100.0	100.0
	9	Percent of men with abnormal findings/needs further evaluation to rule out cancer, were notified of results, and were notified by program within 7 days of when screening^ results received by program	≥80%	100.0	100.0	66.7	100.0	94.4

*Screening means screened with Prostate Specific Antigen (PSA) and/or Digital Rectal Exam (DRE)

^Screening means screened with Prostate Specific Antigen (PSA) or PSA and Digital Rectal Exam (DRE)

Report Date Wednesday, October 10, 2012

Source-CPEST/CRF Cancer Client Database